Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00372827 |
Recruitment Status :
Completed
First Posted : September 7, 2006
Last Update Posted : November 21, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Open-angle Glaucoma Ocular Hypertension Pigment Dispersion Glaucoma | Drug: Brinzolamide 1% added to Travoprost 0.004% | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 245 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double |
Primary Purpose: | Treatment |
Official Title: | Efficacy and Safety of Timolol Maleate 0.5% Compared to Brinzolamide 1% When Added to Travoprost 0.004% in Primary Open-angle Glaucoma or Ocular Hypertension |
Study Start Date : | February 2004 |
Actual Primary Completion Date : | January 2006 |
Actual Study Completion Date : | January 2006 |
- Mean diurnal intraocular pressure at month 3
- Individual intraocular pressures measured at 08:00, 12:00 and 16:00 at month 3.
- Reduction from baseline in mean diurnal intraocular pressure and individual timepoints.
- Visual acuity, Slit lamp biomicroscopy and adverse events during 3 months.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients who are treated with any prostaglandin analogue monotherapy (excluding unoprostone) and who have an intraocular pressure between 19 and 32 mmHg at 08:00 hours.
Exclusion Criteria:
- Under 18 years

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00372827
Germany | |
Mainz Site | |
Mainz, Germany, 55131 |
Study Director: | Anna Grau | Study Manager |
Responsible Party: | Alcon Research |
ClinicalTrials.gov Identifier: | NCT00372827 |
Other Study ID Numbers: |
CM-03-06 |
First Posted: | September 7, 2006 Key Record Dates |
Last Update Posted: | November 21, 2016 |
Last Verified: | May 2008 |
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Hypertension Vascular Diseases Cardiovascular Diseases Eye Diseases |
Travoprost Brinzolamide Antihypertensive Agents Carbonic Anhydrase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |